Paul Averback, MD, DABP, President and CEO, Chairman of the Board
Dr. Paul Averback has been a Director since
September 1995 and is currently the Chairman of the Board. Dr. Paul Averback is the founder, CEO and President of Nymox. He is the inventor of Nymox's spheron-based technologies and co-inventor with other scientists of many of Nymox's other proprietary technologies. Dr. Averback has a vast experience as a successful independent entrepreneur, scientific researcher, medical specialist and front-line medical practitioner. He has successfully negotiated several strategic research collaborations with large multinational pharmaceutical companies in the US, Europe, and Japan. Dr. Averback has extensive firsthand knowledge of health care, including as an emergency room physician, family physician, clinic administrator and university Medical Faculty member. In addition to many issued and pending patents, Dr. Averback has published prolifically in the scientific and medical literature on subjects such as Alzheimer's disease, pharmaceuticals, neuropathology, neuroanatomy, diagnostics, vascular disease, oncology, cytology, congenital disease, embryology, geometrical probability and morphometry. Dr. Averback (MD '75) holds a Diploma of the American Board of Pathology with Special Competence in Neuropathology, was a Medical Research Council Postdoctoral Fellow at Cambridge University, England (1977-1980), and was on the Faculty of Medicine at McGill University (1980-1985).
Randall Lanham, Independent Director
Randall Lanham is an Orange County attorney with extensive experience in securities law and corporate finances. Mr. Lanham has vast experience in both domestic and international corporate legal matters.
Paul F. McDonald, Independent Director
Paul F. McDonald, a graduate in law of McGill University, has been Vice-President of the Montreal Exchange, principal owner and president of a stock-exchange firm, and a longtime director of the Quebec Industrial Development Corporation, and brings a lifetime of experience as a member of the investment industry to the Nymox board.
Professor David Morse, Independent Director
Professor David Morse, Ph.D. is a Professor at the University of Montreal and a world expert in the biochemistry, proteomics and genomics of cell function. Professor Morse has published extensively in the peer-reviewed scientific literature, including papers in journals such as Science, Nature, Cell, Proceedings of the National Academy of Science, and the Journal of Biological Chemistry.
Roger Guy, M.D., Independent Director
Roger Guy, M.D., is a highly experienced medical doctor who has served as a national examiner. Dr. Guy has broad human clinical trial and business managerial experience.
Jack Gemmell, General Counsel and Chief Information Officer
Jack Gemmell, B.Sc.(Hons.), LL.B., has been a Director since June, 2001 and is Nymox's General Counsel and Chief Information Officer. He graduated from the Faculty of Law at the University of Toronto in 1977 and was called to the bar in 1979. He practiced primarily in the area of litigation for over 19 years before joining Nymox in July, 1998 and has substantial business experience.
